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Summary
 
Mature natural killer (NK) cells use Ca
 
2
 
1
 
-dependent granule exocytosis and release of cyto-
toxic proteins, Fas ligand (FasL), and membrane-bound or secreted cytokines (tumor necrosis
factor [TNF]-
 
a
 
) to induce target cell death. Fas belongs to the TNF receptor family of mole-
cules, containing a conserved intracytoplasmic “death domain” that indirectly activates the
caspase enzymatic cascade and ultimately apoptotic mechanisms in numerous cell types. Two
additional members of this family, DR4 and DR5, transduce apoptotic signals upon binding
soluble TNF-related apoptosis-inducing ligand (TRAIL) that, like FasL, belongs to the grow-
ing TNF family of molecules. Here, we report that TRAIL produced or expressed by different
populations of primary human NK cells is functional, and represents a marker of differentiation
or activation of these, and possibly other, cytotoxic leukocytes. During differentiation NK
cells, sequentially and differentially, use distinct members of the TNF family or granule exocy-
tosis to mediate target cell death. Phenotypically immature CD161
 
1
 
/CD56
 
2
 
 
 
NK cells mediate
TRAIL-dependent but not FasL- or granule release–dependent cytotoxicity, whereas mature
CD56
 
1
 
 
 
NK cells mediate the latter two.
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C
 
ytotoxic T lymphocytes (CTLs) and NK cells use a
combination of several mechanisms to lyse different
target cells. These include (
 
a
 
) Ca
 
2
 
1
 
-dependent granule
exocytosis and release of cytotoxic proteins (perforin and
granzymes) from intracytoplasmic granules; (
 
b
 
) FasL, con-
stitutively expressed or induced upon interaction with tar-
get cells and inducing Ca
 
2
 
1
 
-independent, Fas (CD95/Apo
1)-mediated apoptosis; and (
 
c
 
) membrane-bound or se-
creted cytokines (TNF-
 
a
 
) (1–5; for a review, see reference
6). Fas and the TNF-R (CD120a, b) belong to a family of
molecules containing a conserved intracytoplasmic “death
domain” (7, 8) that, through interaction with distinct inter-
mediary adaptor molecules, indirectly results in activation
of the caspase enzymatic cascade (9) and ultimately apop-
totic mechanisms in numerous cell types (7). Additional
members of this family include the death receptors DR4
(R1) and DR5 (R2) (10–12), transducing apoptotic signals
upon binding their soluble ligand, the TNF-related apop-
tosis-inducing ligand (TRAIL [13]). A third receptor (R3),
homologous to the other two in its extracellular domain
but anchored to the membrane via glycosyl phosphatidyl-
inositol and lacking intracellular domain and apoptosis-
inducing capability (14), has been suggested to function as a
decoy receptor, protecting normal cells against TRAIL-
induced apoptosis.
Engagement of the TCR/CD3 complex on T cells in-
duces increased functional expression of FasL (15). Al-
though most CD4
 
1
 
 T cell–mediated cytotoxicity is Fas/
FasL dependent (16), one report indicates Fas/FasL-inde-
pendent CD4
 
1
 
 cell–mediated lysis of certain melanoma cell
lines (17), suggesting that different members in the same
families may also be involved in target cell lysis by CTLs.
Upon stimulation with cytokines (18), appropriate target
cells (4, 19), or Fc
 
g
 
RIIIA ligands (20), functional FasL is
induced on NK cells at significant levels and in appropriate
configuration to cross-link Fas on positive target cells (e.g.,
Jurkat) and induce their death. TRAIL expression, and its
possible role in cytotoxicity mediated by these cells, has not
been analyzed. Here we demonstrate that TRAIL pro-
duced and/or expressed by different populations of human
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primary NK cells is functional and represents a marker of
differentiation and/or activation of these and possibly other
cytotoxic leukocytes.
 
Materials and Methods
 
mAbs and Polyclonal Sera.
 
mAbs to CD2 (B67.1, B67.6), CD4
(B66.6), CD5 (B36.1), CD8 (B116.1), CD11b (B43.4), CD14
(B52.1), CD15 (B40.9), CD56 (B159.5 [21, 22]), CD161/NKR-
P1A (B199.2) used for cell purification (23), and the TNF-
 
a
 
–
neutralizing mAb (B154.2, B154.7 [24]) have been reported pre-
viously. mAbs to CD3 (OKT3), CD21 (THB5), CD34, CD32
(IV.3), CD64 (32.2), and the irrelevant P3x63.Ag8.653 Ig were
produced from cells from the American Type Culture Collection
(Rockville, MD). The Fas-blocking ZB4 mAb and the Fas-trig-
gering CH11 mAb (25) were from Upstate Biotechnology, Inc.
(Lake Placid, NY). The goat anti–mouse Ig used for panning was
produced in our laboratory, adsorbed on human IgG, and affin-
ity-purified on mouse Ig Sepharose before use (26).
 
NK Cell Populations.
 
Immature lineage negative (Lin
 
2
 
) pro-
genitor cell populations were enriched, as described (23), from
umbilical cord blood samples provided by Dr. R. Depp (Depart-
ment of Obstetrics and Gynecology, Thomas Jefferson University
Hospital, Philadelphia, PA). These were 
 
.
 
99% CD3
 
2
 
/CD161
 
2
 
/
CD16
 
2
 
/CD56
 
2
 
 
 
(indirect immunofluorescence [23]), not cyto-
toxic against K562 target cells, and did not express CD16 mRNA
(reverse transcription [RT]-PCR) or CD161 (23; and data not
shown). Their differentiation to NK cells was induced upon co-
culture with the murine bone marrow stromal cell line Sl/Sl
 
4
 
hSCF
 
220
 
 (Sl/Sl
 
4
 
 [27]; provided by Dr. D. Williams, University
of Indiana, Indianapolis, IN) and rIL-2 (50 U/ml; Hoffman-
LaRoche, Nutley, NJ, through the Biological Response Modifiers
Program, National Cancer Institute, Bethesda, MD) or rIL-15 (10
ng/ml, specific activity 2.95 
 
3 
 
10
 
8
 
 U/mg; Immunex Corp., Seat-
tle, WA) during a 20–30-d culture period (23, 28). CD161
 
1
 
/
CD56
 
2
 
 
 
immature and CD56
 
1 
 
mature NK cells were purified (23)
from CD3
 
2
 
/CD161
 
1
 
 cells from 25–30-d cultures with IL-2.
Homogeneous populations of CD3
 
2
 
/CD56
 
1
 
/CD16
 
1
 
 NK cells
were also obtained by negative selection from short-term, 10-d
cultures of umbilical cord blood lymphocytes with 30 Gy–irradi-
ated RPMI-8866 cells (22). Each population contained 
 
.
 
98% cells
expressing the appropriate phenotype (direct immunofluorescence).
 
Soluble TRAIL, Fas, DR4, and DR5.
 
As described (10), Fas,
DR4, and DR5 extracellular ligand-binding domain–Fc fusion
proteins were produced in human 293 cells transiently transfected
with constructs encoding these proteins. Conditioned media were
used as source of the soluble proteins. Recombinant His 6–tagged
TRAIL was produced in bacteria and purified by affinity chroma-
tography on Ni
 
2
 
1
 
 affinity resin.
 
Cytotoxicity and Cell Death.
 
Cell-mediated cytotoxicity
 
 
 
was an-
alyzed in 4- or 6-h 
 
51
 
Cr-release assays using, respectively, the Fas
 
2
 
K562 and the Fas
 
1
 
/DR4
 
1
 
 Jurkat cells (J32 clone) as targets (5 
 
3
 
10
 
3
 
/well) and a series of effector cell numbers; LU were calculated
at 45% specific 
 
51
 
Cr release (21). When indicated, 1 mM EGTA
and 2 mM MgCl
 
2
 
, the Fas-blocking ZB4 or the irrelevant
P3x63.Ag8.653 mAb as control (each 1 
 
m
 
g/ml), the Fas-trigger-
ing CH11 mAb (0.2 
 
m
 
g/ml), the TNF-
 
a
 
–neutralizing mAb (as-
cites, 1:500 dilution), His 6-tagged TRAIL (supernatant, 1:400
dilution), and DR4– and DR5–Fc fusion proteins (supernatants,
1:2 dilution) were present throughout the assay. When indicated,
effector cells were preincubated (5 
 
3 
 
10
 
6
 
 cell/ml, 18 h, 37
 
8
 
C)
with rIL-2 (50 U/ml) and rIL-12 (2 ng/ml, specific activity 4.5 
 
3
 
10
 
6
 
 U/mg protein in an IFN-
 
g
 
–inducing assay; provided by Dr.
S. Wolf, Genetics Institute, Andover, MA). J32 cell death was an-
alyzed in a 6-h 
 
51
 
Cr-release assay with the indicated reagents present
throughout the assay. rTNF-
 
a 
 
(specific activity 10
 
7
 
 U/mg protein
on L929 cells, 
 
a 
 
subline), was provided by Dr. J.S. Price, Cetus
Corp., Emeryville, CA.
 
RT-PCR Analysis.
 
RT-PCR was performed as described (23)
on total RNA extracted from the different cell populations (5 
 
3
 
10
 
4
 
 cells/sample) with RNAzol (Biotecx Laboratories, Houston,
TX). FasL and TRAIL primers (produced at the Kimmel Cancer
Center Nucleic Acid Facility) used for RT were, respectively,
TGGTTGCCTTGGTAGGATTGGGC (5
 
9
 
) and GAGCTTAT-
ATAAGCCGAAAAACG (3
 
9
 
) (29), and AACCTCTGAGGAA-
ACCAT (5
 
9
 
) and TTAGCCAACTAAAAAGGC (3
 
9
 
). 
 
b
 
-actin
primers were published previously (23). RT-PCR products were
identified on agarose gels after ethidium bromide staining.
 
Results and Discussion
 
NK cells induced to differentiate from Lin
 
2 
 
umbilical
cord blood cells in cultures with IL-15 mediated lower lev-
els of cytotoxicity against K562 target cells than those me-
diated by cells from cultures with IL-2 (Fig. 1 
 
a
 
), but cells
from either culture condition, such as mature adult periph-
eral or umbilical cord blood NK cells (26, 30), mediated
similar levels of cytotoxicity after stimulation with IL-2 and
IL-12. In both cases cytotoxicity was restricted to the
CD3
 
2
 
/CD161
 
1
 
/CD56
 
1
 
 NK cell population, the only one
detected in cultures with IL-15 (our unpublished data;
Fig. 1, 
 
b
 
 and 
 
c
 
). An additional immature CD161
 
1
 
/CD56
 
2
 
NK cell population generated in cultures with IL-2 neither
Figure 1. Development of granule exocytosis–dependent cytotoxicity
during NK cell differentiation. (a) Lin2 umbilical cord blood cells were
cultured with the Sl/Sl4 cell line and IL-2 (r, j) or IL-15 (n, h) for 30 d,
incubated (18 h, 378C) without (r, n) or with IL-2 and IL-12 (j, h),
and tested for cytotoxicity on K562 target cells. (b) Cytotoxicity of total
(r), CD561 (h), and CD562 (m) cells from cultures with IL-15, K562
target cells. (c) Cytotoxicity of CD561 (r, m) and CD562 (n, X) NK
cells from cultures with IL-2, K562 (r, h), or Jurkat (m, X) target cells.
Experiment representative of at least three performed with similar results. 
2377
 
Zamai et al. Brief Definitive Report
 
produces IFN-
 
g 
 
(23) nor mediates cytotoxicity against
K562 cells (Fig. 1 
 
c
 
) although, like mature NK cells, cells in
this population contain perforin and enzymatically active
granzyme B (23) and form conjugates with K562 cells (not
shown). The inability of this cell population to kill K562
cells likely reflects a defect in either expression or granule
exocytosis–triggering function of one or more NK cell re-
ceptors activating cytotoxicity or of other accessory mole-
cules involved in it. Interestingly, however, cells in the
same population reproducibly mediated significant levels of
cytotoxicity against the Jurkat cell line (Fig. 1 
 
c
 
).
Killing of K562 cells by umbilical cord (Fig. 2 
 
a
 
) and
adult peripheral blood NK cells (31; data not shown) is
completely Ca
 
2
 
1
 
 dependent, granule exocytosis mediated;
that of the Fas1 Jurkat cell line (25) is only partially so (Fig.
2 b, using umbilical cord blood as effector cells; not shown
with adult PBLs). In this case, activation of the Ca21- and
granule release–independent apoptotic death pathway(s)
depends on engagement of Fas by FasL, expressed or in-
duced at significant levels on the effector cells upon target
cell interaction (18, 31). Thus, the effector cells function
primarily to present target cells with the appropriate con-
figuration of the ligand(s) (FasL) capable of binding and
cross-linking membrane receptor(s) (Fas) that initiate the
target cell apoptotic signals. The Ca21-independent cyto-
toxicity mediated against Jurkat cells by NK cells from cul-
tures with IL-15 or IL-2 (Fig. 2, c and d, respectively) was
inhibited, as expected, in the presence of Fas-blocking
mAb, and no greater inhibition was observed upon further
addition of TNF-a–neutralizing mAb. Thus, analogous to
the observations with freshly purified mature umbilical
cord blood and adult peripheral blood NK cells (31), Ca21-
dependent granule exocytosis and Fas/FasL-dependent cy-
totoxic mechanisms account for most cytotoxic activity of
mature NK cells from Lin2 cells under the culture condi-
tions analyzed.
Interestingly, the immature CD1611/CD562 NK cells
from cultures with IL-2 (Fig. 2 e) also lysed Jurkat cells, al-
though less efficiently than their mature CD561 cell coun-
terparts from the same culture. As expected based on lack
of detectable granule exocytosis upon target cell recogni-
tion (23), Jurkat cell lysis by these cells, unlike that by ma-
ture NK cells, was essentially Ca21 independent (Fig. 2 e).
Immunofluorescence analysis revealed no detectable FasL,
whereas RT-PCR detected constitutive FasL mRNA ex-
pression in all of the NK cell populations (not shown), in
agreement with findings in mature adult human NK cells
(19) and murine NK cell clones (18). However, Fas-block-
ing mAb did not inhibit killing of Jurkat cells by the imma-
ture cells (Fig. 2 e), suggesting that these use soluble or
membrane-bound molecules distinct from FasL to mediate
this effect.
CD1611/CD562 immature NK cells express TNF-a
mRNA constitutively (23), and most produce TNF-a
upon stimulation (our unpublished observations). Two lines
of evidence exclude a significant role of TNF-a, either se-
creted (32) or in membrane-bound form (3), in Jurkat cell
death: (a) no significant 51Cr release above background
was detected from Jurkat cells after a 6-h incubation with
up to 103 U/ml rTNF-a (not shown); and (b) no inhibition
of immature NK cell–mediated Jurkat cell killing was
detected in the presence of a TNF-a–neutralizing mAb,
alone or with added Fas-blocking ZB4 mAb (Fig. 2 e).
Similar results with cells from cultures with IL-2 (con-
taining both mature and immature NK cells) confirmed
that the TNF-a/TNF-R pathway does not participate
significantly in NK cell–mediated Jurkat cell lysis under
the experimental conditions used, and ligands other than
TNF-a on the immature NK cells bind target cell re-
ceptors distinct from TNF-R and Fas but sharing their ap-
optosis-inducing activity.
Unlike K562 cells (13; not shown), Jurkat cells are sensitive
both to Fas-mediated (25; not shown) and to soluble
TRAIL-mediated cytotoxicity (13). Engagement of the
TRAIL receptors DR4 and DR5 (10, 11) by soluble TRAIL
results in apoptosis (33, 34). The J32 Jurkat cell clone used,
like most clones of this cell line, undergoes apoptotic cell
death upon binding either soluble TRAIL or Fas-triggering
mAb (Fig. 3). TRAIL-induced 51Cr release was inhibited
to background levels by a mixture of soluble TRAIL-Rs
(DR4 and DR5), but not by soluble Fas or Fas-blocking
mAb. Conversely, Fas-induced 51Cr release using Fas-trig-
gering mAb was inhibited by the same Fas-blocking mAb,
but not by the mixture of TRAIL-R–Fc fusion proteins.
The lack of inhibition of the anti-Fas mAb–induced cell
death by soluble Fas likely reflects inefficient competition
of this molecule for the anti-Fas binding site on the mAb.
Figure 2. Granule exocytosis–dependent and independent cytotoxicity
of umbilical cord blood NK cell subsets. Mature CD32/CD561/CD161
NK cells from short-term cultures were tested against K562 (a) or Jurkat
target cells (b): cytotoxicity assay without (r) or with EGTA (h), or with
both EGTA and Fas-neutralizing ZB4 mAb (m). Cytotoxicity of total
cells from cultures of Lin2 cells with IL-15 (c) or IL-2 (d) was tested
against Jurkat cells in the presence of EGTA alone (r) or both EGTA
and: (c) Fas-neutralizing mAb (h), (d) TNF-a– (h), or Fas-neutralizing
mAb (m), or a mixture of TNF-a– and Fas-neutralizing mAb (X). (e)
Cytotoxicity of CD32/CD1611/CD562 cells from cultures with IL-2
against Jurkat cells without (r) or with added EGTA alone (*), or with
both EGTA and: anti–TNF-a (h), Fas-neutralizing mAb (m), or a mix-
ture of TNF-a– and Fas-neutralizing mAb (X). Each experiment is repre-
sentative of at least three performed with similar results.2378 TRAIL and FasL Use During NK Cell Differentiation
These data establish that functional Fas and TRAIL-R1
and 2 (DR4 and/or DR5) are expressed on this Jurkat cell
clone with their expected and exclusive specificity.
TRAIL mRNA expression was detectable (by RT-
PCR) in the immature NK cells, although TRAIL protein
was undetectable in DR4/DR5 binding analysis (data not
shown). To determine whether engagement of functional
TRAIL-R by TRAIL, possibly expressed or induced to
significant levels on these cells upon target cell interaction,
elicits Ca21-independent target cell death, we analyzed the
effect of DR4/DR5–Fc fusion proteins on cytotoxicity of
mature and immature NK cells against Jurkat cells. Like the
Ca21-independent lysis mediated by mature NK cells from
short-term (10-d) cultures of primary PBLs (Fig. 4 a), that
mediated by CD1611/CD561 mature NK cells from cul-
tures with IL-15 (not shown) was reproducibly inhibited
by the Fas-blocking mAb, but not by the DR4/DR5–Fc
fusion proteins. Addition of these to the anti-Fas mAb in
the presence of EGTA did not result in inhibition greater
than that mediated by the mAb alone. However, at the
same concentrations, these reagents significantly inhibited
J32 cell lysis by immature NK cells (Fig. 4 b; .75%, as
quantitated based on LU in the cell populations). This indi-
cates that the molecules transducing apoptotic signals in this
case are either or both DR4 and DR5, thus implicating
TRAIL in the cytotoxicity mediated by this cell subset. No
additional inhibition was observed under the same condi-
tions with ZB4 mAb added, excluding a major role, if any,
for the Fas/FasL-dependent cytotoxic pathway by imma-
ture NK cells. The possibility that FasL on the immature
NK cells is induced, and used, at later times after interac-
tion with the appropriate target cells is unlikely, given the
relatively fast kinetics of FasL expression both in T and NK
cells. However, formal proof awaits results of experiments
using additional target cells in longer assays. The possibility
that other (yet to be identified) molecule(s) with ligand
binding specificity identical to TRAIL and in addition to it
are involved in Jurkat cell killing by the immature NK cells
is unlikely, based on a recent report showing anti-TRAIL
Ab–mediated inhibition of Jurkat and melanoma cell lysis
by cytotoxic human CD41 T cell clones (35).
The data reported here provide the first direct evidence
for the use of functional TRAIL, or a molecule with iden-
tical DR4/DR5 binding specificity, by primary human NK
cells, and point to this as a marker of differentiation of these
and possibly other cytotoxic cell types. Our results also in-
dicate a switch in the surface molecules used for target cell
recognition and/or lysis during NK cell differentiation.
TRAIL–TRAIL-R interactions represent the first major
(but possibly not exclusive) mechanism of target cell lysis
used by NK cells to mediate their functions as innate effec-
tors of defense, and this ability is acquired by NK cells at a
specific, phenotypically identifiable stage of differentiation
(exclusively CD1611) that precedes acquisition of the abil-
ity to mediate granule exocytosis– or FasL-dependent cyto-
toxicity (23; and this paper) and to produce IFN-g (23).
Interesting and testable questions are raised by these data
related to whether (a) the same molecules are used by NK
cells at different stages of differentiation to kill other target
cells; (b) TRAIL and FasL are also markers of differentia-
tion of other cytotoxic cells, or of specific functional capa-
bilities acquired by activated mature cytotoxic effector cells
or lymphocyte subsets, phenotypically similar to the imma-
ture CD1611/CD562 NK cells and present in peripheral
blood (23). This possibility is suggested by preliminary data
(RT-PCR, not shown) indicating TRAIL mRNA expres-
sion in mature NK cells; and (c) like granule exocytosis (for
a review, see reference 36), both FasL- and TRAIL-depen-
dent cytotoxicity are negatively regulated by MHC-bind-
Figure 3. Fas and TRAIL sensitivity of Jurkat T cells. 51Cr-labeled J32
Jurkat cells were incubated for 6 h with the indicated reagents; released
radioactivity was measured in the supernatants from triplicate wells. His
6–tagged TRAIL (1:400 dilution), DR4– and DR5–, and Fas–Fc fusion
molecules (each 1:2 dilution), Fas-blocking ZB4 and Fas-stimulating
CH11 mAb (1 and 0.2 mg/ml, respectively) were present throughout the
assay as indicated. The experiment is representative of two performed
with similar results.
Figure 4. Differential use of TRAIL and FasL by immature and mature
NK cells.  Cytotoxicity of mature CD1611/CD561 (a) and CD1611/
CD562 NK cells (b) purified from 30-d cultures of Lin2 umbilical cord
blood cells with IL-2 and the Sl/Sl4 cell line (reference 23) was measured
in a 6-h assay against Jurkat target cells without (r) or with both EGTA
and: control P3x63.Ag8.653 Ig (h), DR4– and DR5–Fc chimeric pro-
teins (m), anti–Fas-blocking mAb ZB4 (X), or a mixture of DR4/DR5–Fc
fusion proteins and ZB4 mAb (*) (concentrations as in the legend to Fig.
3) throughout the assay. Experiment representative of four performed
with similar results.2379 Zamai et al. Brief Definitive Report
ing receptors inhibiting cytotoxicity. TRAIL-Rs, expressed
on numerous cell types, have been shown to be functional
on transformed, but not normal cell-derived cell lines (37).
Definition of the expression and functionality of these re-
ceptors on primary tumor cells and hematopoietic cells at
distinct stages of differentiation or activation/proliferation
is essential to establish whether the use of TRAIL rather
than FasL by immature NK cells, or even (a) phenotypi-
cally identical subset among mature NK cells (23), may en-
dow these cells with (relative) specificity in the control of
tumor and possibly immature hematopoietic cell growth.
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